Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood

Status Not yet recruiting

Clinical Trial Summary

This study will access the safety and efficacy of the Viatar™ Oncopheresis System to remove a meaningful quantity of circulating tumor cells from the blood of subjects' with breast, colon or prostate solid tumor cancers in a single treatment. CTC reduction will be measured as the change in circulating tumor cells as determined before and after treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03058809
Study type	Interventional
Source	Viatar LLC
Contact	Michael A Patz
Phone	9787128210
Email	michael.patz@viatarctcsolutions.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	September 2018
Completion date	May 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Not yet recruiting	`NCT04931420` - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels	Phase 2
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05036681` - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma	Phase 2
Withdrawn	`NCT00005030` - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver	Phase 1
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting	`NCT04085029` - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Not yet recruiting	`NCT05981170` - Rurality Adapted Physical Activity Sport Health
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Completed	`NCT01302808` - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT00918645` - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis	N/A
Withdrawn	`NCT00769990` - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases	Phase 1/Phase 2
Completed	`NCT00795678` - Chemotherapeutic Agents in Brain/Breast	N/A
Completed	`NCT00557102` - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung	Phase 2
Recruiting	`NCT00398437` - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer	N/A
Active, not recruiting	`NCT00436735` - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors	Phase 1